NUIX LIMITED AND CONTROLLED ENTITIES

Appendix 4E and Preliminary Final Report

For the year ended 30 June 2024

A.B.N. 80 117 140 235

A.C.N. 117 140 235

ASX Code: NXL

Table of Contents

Appendix 4E

Results for announcement to the market

Statutory results for the year ended 30 June	% change	2024 $000	2023 $000
Revenue from ordinary activities	Improved 20.9%	220,617	182,465
Profit/(Loss) from ordinary activities after tax attributable to members	Improved 189.9%	5,026	(5,589)
Profit/(Loss) for the year attributable to members	Improved 189.9%	5,026	(5,589)

Other information

Dividends

It is not proposed that dividends be paid for the year ended 30 June 2024 (30 June 2023: nil).

Dividend reinvestment plan

Nuix Limited has not implemented a dividend reinvestment plan.

Net Tangible Assets ('NTA') backing[1]

As at 30 June	2024	2023
NTA[1] (thousands of dollars)	45,283	22,317
Number of shares (thousands)	323,529	317,499
NTA per share (cents)	14.0	7.0

Supplementary comments

Additional information may be found in the media release and investor presentation lodged with the ASX on 19 August 2024 and the Operating and financial review.

Entities over which control, joint control or significant influence was gained or lost

During the year, the Group acquired all the shares of Rampiva Global, LLC and Rampiva Technology, Inc. (collectively Rampiva). The Group has no interests in associates or joint ventures.

Audit

The Preliminary Final Report has been prepared in accordance with ASX Listing Rule 4.3A and has been derived from the unaudited Annual Financial Report. In line with last year and in accordance with the *Corporations Act 2001*, the Preliminary Final Report is unaudited and contains disclosures which are extracted or derived from the Annual Financial Report for the year ended 30 June 2024. The Annual Financial Report is being audited and is expected to be made available in September 2024.

[1] Net Tangible Assets have been calculated as net assets, adjusted for intangible assets and net deferred taxes.

Operating and financial review

The operating and financial review for the year ended 30 June 2024 has been designed to provide shareholders with a clear and concise overview of the Group's operations, financial position, business strategies and prospects. The review also discusses the impact of key transactions and events that have taken place during the reporting period, to allow shareholders to make an informed assessment of the results.

In line with ASIC's Regulatory Guide 247 'Effective Disclosure in an Operating and financial review' this review of operations is prepared to assist shareholders to understand Nuix's business performance and the factors underlying its results and financial position. It complements the disclosures in the Preliminary Final Report.

The following commentary should be read with the consolidated financial statements and the related notes in the Financial Report.

Non-GAAP measures have been included, in particular Annualised Contract Value (ACV), as Nuix believes they provide information for readers to assist in understanding the company's financial performance. Non-GAAP financial measures should not be viewed in isolation or considered as substitutes for measures reported in accordance with Australian equivalents to International Financial Reporting Standards.

1. Principal activities

Nuix is a leading provider of investigative analytics and intelligence software which empowers organisations to simply and quickly find meaningful insights from large amounts of unstructured data.

Nuix offers a software platform (Nuix platform) comprising a powerful proprietary data processing engine (Nuix Engine) and several software applications. It has been developed in-house, shaped by feedback from long-standing government and private sector customers since 2000, and assists customers in solving complex data challenges. The Nuix platform operates at a "forensic level", providing users with a highly detailed, contextualised and legally defensible way of viewing and interacting with data.

No significant change in the nature of these activities occurred during the year.

2. Significant changes in state of affairs

The Group acquired all the shares of Rampiva Global, LLC and Rampiva Technology, Inc (collectively Rampiva) on 1 July 2023, a workflow automation and job scheduling provider.

The Group also entered into a Facility Agreement with The Hongkong and Shanghai Banking Corporation, Sydney Branch (HSBC) to provide an AUD $30,000,000 multicurrency revolving credit facility.

There were no other significant changes to the state of affairs of the Group during the year.

3. Business strategies

During the financial year, Nuix made significant progress on building and commercialising its unified platform, Nuix Neo.

Nuix Neo is an AI-enriched platform that helps customers identify, process and understand complex data in ways that are faster, easier and smarter. Accessed through a browser-based, collaborative interface, Nuix Neo places Nuix's market-leading processing at the centre of an integrated, solutions-based platform. The platform includes end-to-end automation, investigative analytics and AI-enabled workflows. Nuix Neo creates a new, extended customer offering, with the capability to be deployed on premise or in a customer cloud and enables on-demand scalability through a consumption-based subscription model.

Nuix Neo represents the underlying platform for specific use case solutions. During the year, Nuix created and released three Nuix Neo use case solutions: Data Privacy, Investigations and Legal. Leveraging the capabilities of the Nuix Neo platform, these use case solutions offer a step-change in Nuix's customer offering.

4. Group performance

Statutory revenue for the year was $220,617,000, up 20.9% on the prior corresponding period. Statutory revenue can display a greater degree of variability than Annualised Contract Value (ACV) due to the accounting treatment of multi-year deals. The proportion of multi-year deals for the year rose slightly to 31%, from 30% in the prior year.

Annualised Contract Value (ACV)[1]

Annualised Contract Value (ACV) is a non-IFRS measure that gives an indication of the annualised "run rate" of Nuix's contract value at a given point in time, adjusting for the sometimes volatile impacts of multi-year deals on measures such as statutory revenue.

Annualised Contract Value (ACV) at 30 June 2024 was $211,506,000, up 14.0% compared to 30 June 2023, driven by stronger net upsell to existing customers, including sales of Nuix Neo, and continued low churn. Sales of Nuix Neo contributed approximately $12,137,000 to the overall ACV outcome.

Subscription ACV is a component of Total ACV and is an important indicator of ACV that is generally recurring in nature. Subscription ACV grew 18.2% year on year to $200,806,000 comprising 95% of overall ACV. "Other ACV", comprising short-term (less than 12 month) and perpetual licences, and services ACV, fell 31.9% on the prior year, to $10,700,000 on lower perpetual licence sales.

Regionally, North America achieved the strongest growth in ACV, up 18.8% in the financial year, to $114,146,000. EMEA ACV rose 6.4%, to $53,285,000. Asia Pacific ACV rose 11.8% to $44,075,000.

Traditional module-style licences contributed the largest proportion of statutory revenue, although revenue from consumption-style licences is increasing as a proportion of overall revenue, driven by the growth in Nuix Neo and Discover SaaS.

Stronger revenue growth combined with general cost containment meant statutory EBITDA was materially higher than the prior corresponding period, up 60.2% to $55,867,000.

Sales and Distribution expenses were higher over the financial year, on investment in key roles and growth-related expenses.

Research and development spend was lower in the year compared to the prior period, as several efficiency initiatives were implemented. As a proportion of revenue, research and development spend fell to 24%, compared to 33% in the prior year.

General and Administrative expenses rose compared to the prior year in relation to ATO review and derecognition of R&D deferred tax asset, along with higher equity compensation costs.

Net non-operational legal costs of $8,547,000 (net of insurance recoveries) were slightly higher than the prior year amount of $7,816,000.

The Group reported a Net Profit After Tax of $5,026,000 for the financial year, compared to a Net Loss After Tax of $5,589,000 in the prior corresponding period.

[1] Annualised Contract Value (ACV) is an adjusted, non-IFRS measure and does not represent Total Revenue in accordance with AAS or Nuix's accounting policies or cash receipts from customers. ACV is used by Nuix to assess the total contract value of its software contracts on an annualised basis (removing fluctuations from Multi-Year Deal contracts in Nuix's Total Revenue which results from its revenue recognition policies). The calculation of ACV at the end of the relevant financial period adjusts Total Revenue to account for: A) Revenue generated from Subscription Licences with a term of 12 months or more, as well as Consumption Licences which exist at the end of the relevant financial period as if those contracts' revenues were generated (and recognised) in each financial year on a rateable basis over the relevant contract period, expressed on an annualised basis; B) last 12 month contribution from short term Software Licences (including Perpetual Licences) or other Software Licences with a term of less than 12 months, excluding Consumption Licences; and C) the last 12 month contribution of services and third party software sales.

5. Group financial position

The Group had a closing cash balance of $38,032,000 at 30 June 2024, up 28.5% from $29,588,000 in the previous financial year.

Operating cash flow reflected the increased operating leverage achieved. Even including the impact of non-operational legal payments, and payments associated with the acquisitions of Topos and Rampiva, overall free cash flow was strongly positive, rising to $11,888,000, up 193% on the prior year.

The overall increase in cash and cash equivalents was driven by stronger customer receipts and general cost containment. Research and development continues to be funded by operational cash flow.

The $30 million revolving credit facility established during the year remains undrawn.

Consolidated statement of comprehensive income

For the year ended 30 June 2024

	Notes		2024 $000		2023 $000
Revenue	3		220,617		182,465
Cost of goods sold			(21,645)		(22,949)
Gross profit			**198,972**		**159,516**
Sales and distribution			(73,539)		(65,039)
Research and development			(65,060)		(58,382)
General and administration					
Non-operational legal fees[1]		(8,547)		(7,816)	
Other general and administration		(43,988)		(35,398)	
Total general and administration			(52,535)		(43,214)
Remeasurement of government grant income[2]	6		(3,051)		-
Other income	4		969		1,319
Net realised and unrealised foreign exchange gains			873		735
Operating profit/(loss)			**6,629**		**(5,065)**
Finance costs			(890)		(1,220)
Finance income			292		-
Fair value gain on contingent consideration			2,137		1,011
Profit/(Loss) before income tax			**8,168**		**(5,274)**
Income tax expense	6		(3,142)		(315)
Profit/(Loss) for the year			**5,026**		**(5,589)**
Other comprehensive income/(loss)					
Items that may be reclassified to profit or loss					
Exchange differences on translation of foreign operations			(2,115)		4,074
Other comprehensive income, net of tax			(2,115)		**4,074**
Total comprehensive income/(loss) for the year, net of tax			**2,911**		**(1,515)**
Earnings per share					
Basic	19		0.02		(0.02)
Diluted	19		0.02		(0.02)

The consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

[1] Net of Insurance recoveries.

[2] Refer to discussion on change in estimates associated with an uncertain tax position and related impact on measurement of government grant income, deferred government grant income and deferred tax assets in Note 6 to the preliminary final report.

Consolidated statement of financial position

As of 30 June 2024

	Notes	2024 $000	2023 $000
Current assets			
Cash and cash equivalents	7	38,032	29,588
Trade and other receivables (including contract assets)	8	66,844	68,534
Other current assets	9	8,652	7,323
Current tax assets		1,832	1,441
Total current assets		**115,360**	**106,886**
Non-current assets			
Deferred tax assets		5,556	3,958
Intangible assets	10	244,401	244,567
Property and equipment		2,288	2,944
Right of use assets		8,277	8,647
Trade and other receivables (including contract assets)	8	21,664	12,566
Total non-current assets		**282,186**	**272,682**
Total assets		**397,546**	**379,568**
Current liabilities			
Trade and other payables	11	35,334	28,655
Deferred revenue	12	38,444	38,998
Provisions		3,177	3,000
Lease liabilities		3,189	3,028
Other current liabilities	13	3,949	9,839
Total current liabilities		**84,093**	**83,520**
Non-current liabilities			
Deferred revenue	12	7,683	15,947
Provisions		1,239	1,171
Lease liabilities		6,583	8,088
Deferred tax liabilities		8,548	-
Other non-current liabilities	13	2,708	-
Total non-current liabilities		**26,761**	**25,206**
Total liabilities		**110,854**	**108,726**
Net assets		**286,692**	**270,842**
Equity			
Issued capital	15	376,947	370,696
Reserves	16	(151,602)	(156,175)
Retained earnings		61,347	56,321
Total equity		**286,692**	**270,842**

The consolidated statement of financial position should be read in conjunction with the accompanying notes.

Consolidated statement of changes in equity

For the year ended 30 June 2024

	Issued capital $000	Share based payment reserve $000	Foreign currency translation reserve $000	Treasury share reserve $000	Retained earnings $000	Total equity $000
Balance at 1 July 2022	**370,696**	**(168,731)**	**5,192**	-	**61,910**	**269,067**
Loss for the year	-	-	-	-	(5,589)	(5,589)
Other comprehensive income	-	-	4,074	-	-	4,074
Total comprehensive income/(loss)	**-**	**-**	**4,074**	**-**	**(5,589)**	**(1,515)**
Transactions with owners						
Share-based payments	-	3,466	-	-	-	3,466
Treasury shares acquired	-	-	-	(176)	-	(176)
Treasury shares transferred to settle share-based payment arrangement	-	(176)	-	176	-	-
Balance at 30 June 2023	**370,696**	**(165,441)**	**9,266**	**-**	**56,321**	**270,842**
Balance at 1 July 2023	**370,696**	**(165,441)**	**9,266**	**-**	**56,321**	**270,842**
Profit for the year	-	-	-	-	5,026	5,026
Other comprehensive income/(loss)	-	-	(2,115)	-	-	(2,115)
Total comprehensive income/(loss)	-	-	(2,115)	-	5,026	2,911
Transactions with owners						
Shares issued in relation to acquisition of Rampiva	3,041	-	-	-	-	3,041
Shares issued in relation to acquisition of Topos	3,210	-	-	-	-	3,210
Share-based payments	-	6,688	-	-	-	6,688
Balance at 30 June 2024	**376,947**	**(158,753)**	**7,151**	**-**	**61,347**	**286,692**

The consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Consolidated statement of cash flows

For the year ended 30 June 2024

	Notes	2024 $000	2023 $000
Cash flows from operating activities			
Receipts from customers		200,224	165,188
Payments to employees and suppliers		(148,199)	(132,366)
Interest received		63	19
Income tax paid		(1,745)	(277)
Net cash provided from operating activities		**50,343**	**32,564**
Cash flows from investing activities			
Payments for software development costs		(32,358)	(37,233)
Acquisition of Rampiva, net of cash acquired	18	(3,563)	-
Payments of consideration for Topos Labs, LLC	13	(1,793)	(6,890)
Purchase of property and equipment		(741)	(1,300)
Net cash used in investing activities		**(38,455)**	**(45,423)**
Cash flows from financing activities			
Payments of principal on lease liabilities		(2,902)	(2,880)
Interest paid		(544)	(1,239)
Purchase of treasury shares		-	(176)
Net cash used in financing activities		**(3,446)**	**(4,295)**
Net change in cash and cash equivalents		8,442	(17,154)
Cash and cash equivalents at beginning of financial year		29,588	**46,846**
Exchange differences on cash and cash equivalents		2	(104)
Cash and cash equivalents at end of year		**38,032**	**29,588**

The consolidated statement of cash flows should be read in conjunction with the accompanying notes.

Table of contents

Notes to the Preliminary Final Report

1. Basis of preparation

1.1 Statement of compliance

The Preliminary Final Report (the Report) has been prepared in accordance with Australian Accounting Standards (AASBs) adopted by the Australian Accounting Standards Board and the *Corporations Act 2001*. The Report also complies with International Financial Reporting Standards and Interpretations ('IFRICs') adopted by the International Accounting Standards Board.

The Report is presented in Australian dollars, which is the functional currency of Nuix Limited, and has been prepared on the basis of historical cost except in accordance with relevant accounting policies where assets and liabilities are stated at their fair values.

The Annual Financial Report is in the process of being audited. This Report should also be read in conjunction with any public announcements made by Nuix during the year in accordance with the continuous disclosure requirements arising under the *Corporations Act 2001* and ASX Listing Rules.

Nuix is a company of the kind referred to in ASIC Corporations (Rounding in Financial / Directors' Reports) Instrument 2016/191. In accordance with that instrument, all financial information presented has been rounded to the nearest thousand dollars, unless otherwise stated.

1.2 Significant accounting policies

The significant accounting policies applied by Nuix in this Preliminary Final Report are the same as those applied by the Group in the Nuix Limited Annual Report for the year ended 30 June 2023.

1.3 Critical accounting estimates and judgments

The preparation of the consolidated financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected. In preparing this Report, judgements made by management in the application of AASBs that have a significant effect on the consolidated financial statements and estimates with a significant risk of material adjustment in future periods were the same as those applied to the Nuix Annual Report for the year ended 30 June 2023.

1.4 Going concern

At 30 June 2024, the Group is in a net current asset position of $31,267,000. At 30 June 2024. The Group had $38,032,000 available cash and cash equivalents (refer to Note 7) and the Group was cash flow positive during the year, notwithstanding ongoing non-operational legal fees and cash payments relating to the acquisitions of Rampiva and Topos Labs. The financial statements have been prepared on a going concern basis.

In preparing these financial statements, the Group has prepared, and the Directors have considered cash flow forecasts, taking into account information currently available regarding current conditions and those, at least but not limited to, twelve months from the end of the reporting period. Important to these cash flows are the assumptions used regarding net cash inflows in FY25, and the potential outcomes and timings of the regulatory and litigation matters as discussed in Note 20. The uncertainties attached to the unknown outcomes of the litigation matters together with the potential business impacts of the ongoing litigation matters and their attendant reputational and financial impacts, gave rise to the Group concluding that while there are uncertainties related to events or conditions that may, depending on the circumstances, cast doubt on the entity's ability to realise its assets and discharge its liabilities in the normal course of business, it remains appropriate that the financial statements be prepared on a going concern basis.

In forming this conclusion, the Directors have considered a cash flow forecast which considers the following assumptions, associated risks and mitigating factors:

- cash flow forecasts include new pricing plans, customer migration to Nuix Neo, growth in revenue supported by the continued investment in sales capability and continued product development along with ongoing legal fees;
- recent results of operating activities aligned with the Nuix strategy and improved NDR% have been taken into account when setting revenue forecasts used to derive forecast cash receipts;
- the potential timing and quantum of any adverse outcomes from the current litigation action by the regulator as detailed in Note 20. In applying the assumptions and judgements, we have had regard to the penalty regime, views of our advisors and potential likelihood of outcomes. The Directors also have had regard to the Group's options to appeal any adverse judgement, should one arise, and the associated usual appeal hearing timeframes. With the exception of legal fees, the forecasts do not include cash outflows related to any claims;
- the Company having entered into a debt financing agreement with The Hongkong and Shanghai Banking Corporation, Sydney Branch (HSBC) to provide an AUD $30,000,000 multicurrency revolving credit facility under a Facility Agreement, with a maturity of three years, to be used for general corporate purposes as detailed in Note 14. No amount has been drawn during the year.

The outcomes of these indicate sufficient cash balances throughout the next 12 months.

Based on the above, the Directors are satisfied that the Group will be able to continue to operate and have the ability to discharge its liabilities in the normal course of business for a minimum of the next twelve months.

1.5 Significant events and transactions

During the year ended 30 June 2024, the Group has acquired Rampiva (refer Note 18), and entered into a Facility Agreement with The Hongkong and Shanghai Banking Corporation, Sydney Branch (HSBC) (refer Note 14).

The Group also made a change in estimate relating to the measurement of historically recognised government grant income associated with accounting for R&D offsets claimed in the years FY16 through FY22 (refer Note 6).

There were no other significant changes to the state of affairs of the Group during the year.

2. Segment information

2.1 Segment performance

The Group manages its operations as a single business operation and there are no parts of the Group that qualify as operating segments under AASB 8 Operating Segments. The CEO (Chief Operating Decision Maker or "CODM") assesses the financial performance of the Group on an integrated basis only and accordingly, the Group is managed on the basis of a single segment. Information presented to the CODM on a monthly basis is categorised by type of revenue as provided below. Further, earnings before interest, tax and depreciation and amortisation (EBITDA) is used to assess the performance of the business.

	2024 $000	2023 $000
Software	212,377	176,691
Services	8,205	5,335
Revenue from events (sponsorship and ticket sales)	35	439
Total revenue	**220,617**	**182,465**

In general, a large amount of revenue was generated from customers that are global and transactions that cross multiple countries where the source of revenue can be unrelated to the location of the users accessing the software. Accordingly, the Group is managed as a single segment.

Key elements adjusted from statutory loss after tax to derive segment EBITDA are as follows:

	2024 $000	2023 $000
Net profit/(loss) after tax	5,026	(5,589)
Add: Income tax expense	3,142	315
Profit/(loss) before income tax	**8,168**	**(5,274)**
Add: Depreciation and amortisation	50,111	40,691
Add: Interest expense	890	1,220
Less: Net foreign exchange gains	(873)	(735)
Less: Interest income	(292)	-
Less: Fair value gain on contingent consideration	(2,137)	(1,011)
EBITDA	**55,867**	**34,891**

2.2 Geographic information

Revenue generated by location of customer[1]	2024 $000	2023 $000
Asia Pacific	33,670	41,698
Americas	129,666	91,740
Europe, Middle East and Africa (EMEA)	57,281	49,027
	220,617	**182,465**

Non-current assets by geographic location	2024 $000	2023 $000
Asia Pacific	140,749	143,400
Americas	139,494	128,137
Europe, Middle East and Africa (EMEA)	1,943	1,145
	282,186	**272,682**

[1] The amounts for revenue by region in the following table are based on the invoicing location of the customer.

3. Revenue

	2024 $000	2023 $000
Software	212,377	176,691
Services	8,205	5,335
Revenue from events (sponsorship and ticket sales)	35	439
Total revenue	**220,617**	**182,465**

Disaggregation of revenue

The Group disaggregates revenue by categories shown in the tables below.

Revenue by type

	2024 $000	2023 $000
Subscription licences	127,272	115,428
Perpetual licences	29,982	30,317
Consumption licences	55,123	30,946
Total licence revenues (including related support and maintenance)	**212,377**	**176,691**
Professional services	8,205	5,335
Revenue from events (sponsorship and ticket sales)	35	439
Total other revenues	**8,240**	**5,774**
Total revenues	**220,617**	**182,465**

Timing of revenue recognition

	2024 $000	2023 $000
Point in time	140,290	114,933
Over time	80,327	67,532
	220,617	**182,465**

4. Other income

	2024 $000	2023 $000
Government grant income	904	1,080
Other income	65	239
	969	**1,319**

Government grants recognised as other income for the current financial year relates to benefits received under the Research and Development Tax Incentive regime in excess of the statutory income tax rate.

5. Profit/(Loss) for the year

The profit/(loss) for the year has been arrived at after charging the following items:

	2024 $000	2023 $000
Expenses (included in general and administration)		
Legal fees – operational	5,282	2,909
Legal fees – non-operational[1]	8,547	7,816
Bad debts expense	100	956
Low value / short term leases	1,046	1,018
Employee benefit expenses, inclusive of share-based payments		
Support and operations (costs of goods sold)	6,058	5,929
Sales and distribution	62,691	52,646
Research and development	16,499	19,227
General and administration	19,196	15,992
Depreciation and amortisation		
Sales and distribution	810	1,895
Research and development	46,550	36,688
General and administration	2,451	1,808
Cost of goods sold	300	300
Interest expense	890	1, 220
Remeasurement of government grant income[2]	(3,051)	-
Fair value gain on contingent consideration	(2,137)	(1,011)

6. Taxation of our global operations

	2024 $000	2023 $000
Current tax expense		
Current tax on profits for the year	1,920	1,430
Changes in estimates related to prior years	522	(312)
Total current tax expense	**2,442**	**1,118**
Deferred tax expense		
Increase/(decrease) in deferred tax assets	5,358	(2,495)
(Decrease)/Increase in deferred tax liabilities	(2,517)	1,075
Decrease in deferred tax assets (initially recognised directly in equity)[3]	788	788
Changes in estimates related to prior years	(2,929)	(171)
Total deferred tax benefit/(expense)	**700**	**(803)**
Income tax expense	**3,142**	**315**

[1] Relates to costs for Group's defences to the actions brought as disclosed in Note 20. This amount is presented net of amounts received from insurers.

[2] Refer to discussion on change in estimates associated with an uncertain tax position and related impact on measurement of government grant income, deferred government grant income and deferred tax assets in Note 6.

[3] Section 40-880 deduction recognized and amortized over 5 years in respect to the IPO costs incurred in December 2020, for the portion that was recognised directly in equity.

Uncertainty over income tax treatments

In the current and prior periods as disclosed in the Prospectus and previous annual financial reports, the Group has exercised judgement in recognising and measuring Research and Development ('R&D') tax offsets available under Australian tax legislation relating to eligible R&D expenditure incurred on eligible overseas development activities and related eligible core Australian activities.

In respect of the Group's endpoint Cyber Security Project ("Endpoint Project"), the relevant overseas and Australian activities were the subject of an Advance Finding and Overseas Finding for the years ended 30 June 2016 (FY16) to 30 June 2018 (FY18). As the registered R&D activities were considered to be continuing into the year ended 30 June 2019 (FY19) claims continued to be made in relation to spend in FY19.

The Group has exercised judgement in prior years in assessing that it was probable that the relevant taxation authority would accept the Group's tax treatment for the Endpoint Project for the years FY16 to FY19. This judgement remained consistent in the preparation of the Groups' financial statements from FY20 through 1H FY24.

In August 2022, the Group concluded an early engagement process with the ATO to seek certainty in relation to the eligibility of the overseas development expenditure on the Endpoint Project. At the conclusion of this process, having considered the observations and recommendations provided by the ATO as part of the early engagement, the Group continued to consider that it was likely that the tax authority would accept its filed positions and made disclosures in its FY22 financial statements on that basis.

Despite the outcome of the early engagement process with the ATO, in 1H FY24, the regulator commenced a review of Nuix's tax affairs covering the period from FY16 to FY22. As a result of certain developments in the ATO's review and due to additional information which has been identified in the course of Nuix responding to the ATO's requests, the Group has reconsidered the likelihood of the taxation authority continuing to accept the Group's tax treatment for the Endpoint Project.

As a result, and while the matter is finely balanced, the Group considers there may be a risk that the tax authority would no longer accept the Group's tax treatment for the Endpoint Project for the years FY16 to FY19 and has remeasured various tax balances.

In determining the impact of this change in judgement, consideration has been given as to whether the spend giving rise to the R&D offsets in the lodged returns subject to scrutiny would otherwise be deductible for tax purposes in the year of expenditure and not treated as capital or capital in nature.

Accounting standards require the benefit from the R&D offset above the 30% corporate tax rate be subject to government grant accounting. As a result, any changes to R&D offsets recognised from amounts claimed in relation to R&D activities, has an impact on amounts recognised as other income.

The impact of the change in accounting estimate in the current period has been that there is a reduction in deferred tax assets of $3,906,000, a reduction in deferred government grant income of $796,000, a reversal of historically recognised government grant income of $2,666,000 and a reduction in government grant income recognised in the current year of $385,000. The impact of the change in estimate on the FY24 profit and loss is $3,051,000. The change in estimate has not resulted in the identification of any shortfall in payments for income tax in previous periods, and is a non-cash adjustment.

7. Cash and cash equivalents

	2024 $000	2023 $000
Bank balances	38,032	29,588
Total cash and cash equivalents	**38,032**	**29,588**

8. Trade and other receivables (including contract assets)

	2024 $000	2023 $000
Trade receivables	36,639	41,634
Provision for impairment of trade receivables and contract asset	(1,791)	(1,702)
Contract assets	53,322	40,422
Other investment (cash backed bank guarantee)	-	746
Other deposits	338	-
Total trade and other receivables	**88,508**	**81,100**

Presentation of balances

	2024 $000	2023 $000
Current	66,844	68,534
Non-current	21,664	12,566
Total trade and other receivables	**88,508**	**81,100**

Ageing of overdue receivables

	2024 $000	2023 $000
1 – 3 months	3,810	6,918
4 – 6 months	153	1,234
Over 6 months	1,169	736
	5,132	**8,888**

9. Other current assets

	2024 $000	2023 $000
Prepayments	5,464	5,504
Costs of obtaining contracts	1,677	1,485
Other receivables	1,511	334
Total other current assets	**8,652**	**7,323**

10. Intangible assets

	Goodwill $'000	External licenses $'000	Brand $'000	Customer relationships $000	Intellectual property $'000	Total $'000
Year ended 30 June 2023						
Balance at 1 July 2022	18,401	1,031	570	-	217,123	237,125
Effect of movements in exchange rates - cost	711	65	32	-	4,821	5,629
Effect of movements in exchange rates - accumulated amortisation & impairment	-	(64)	(14)	-	(1,663)	(1,741)
Additions	-	-	-	-	39,940	39,940
Amortisation	-	(348)	(210)	-	(35,828)	(36,386)
Balance at 30 June 2023	**19,112**	**684**	**378**	**-**	**224,393**	**244,567**
Carrying amount at 30 June 2023						
At cost	19,112	3,851	855	-	380,983	404,801
Accumulated amortisation & impairment	-	(3,167)	(477)	-	(156,590)	(160,234)
Balance at 30 June 2023	**19,112**	**684**	**378**	**-**	**224,393**	**244,567**
Year ended 30 June 2024						
Balance at 1 July 2023	19,112	684	378	-	224,393	244,567
Effect of movements in exchange rates - cost	(213)	(13)	(8)	-	(1,114)	(1,348)
Effect of movements in exchange rates - accumulated amortisation & impairment	-	14	4	-	690	708
Acquisition via business combination[1]	3,872	-	111	139	8,318	12,440
Additions	-	-	-	-	34,464	34,464
Amortisation	-	(309)	(297)	(77)	(45,747)	(46,430)
Balance at 30 June 2024	**22,771**	**376**	**188**	**62**	**221,004**	**244,401**
Carrying amount at 30 June 2024						
At cost	22,771	3,838	958	139	422,651	450,357
Accumulated amortisation & impairment	-	(3,462)	(770)	(77)	(201,647)	(205,956)
Balance at 30 June 2024	**22,771**	**376**	**188**	**62**	**221,004**	**244,401**

[1] Following the acquisition of Rampiva, the US Dollar denominated balances of the intangible assets acquired as a part of the business combination are: Goodwill: US $2,583,000; Brand: US $74,000; Customer relationships: US $93,000; Intellectual property: US $5,548,000.

The difference between the Australian Dollar denominated balances in Note 10 and Note 18 arises from the movement in the foreign currency exchange rates between the acquisition date 1 July 2023 and the yearend date 30 June 2024. The balances in Note 18 were presented using foreign exchange rate at 1 July 2023 (1.51 AUD to 1 USD) whereas the balances in Note 10 were translated using the foreign exchange rate at 30 June 2024 (1.50 AUD to 1 USD).

11. Trade and other payables

	2024 $000	2023 $000
Sundry payables and accrued expenses	29,907	22,397
Trade payables	3,201	4,215
Customer deposits	197	54
Payroll tax and other statutory liabilities	644	852
Indirect taxes payable	1,385	1,137
Total trade and other payables	**35,334**	**28,655**

12. Deferred revenue

	2024 $000	2023 $000
Customer-related (contract liabilities)		
Support and maintenance on term licences	13,528	20,669
Term licences (billed) commencing post balance date	1,804	3,890
Support and maintenance on perpetual licenses	16,026	16,077
Consumption income	7,987	7,510
Professional services income	4,924	3,060
	44,269	**51,206**
Tax incentive-related		
Research and development	1,858	3,739
Total deferred revenue	**46,127**	**54,945**

Movements during the year of tax incentive related deferred revenue

	2024 $000	2023 $000
Opening balance	3,739	4,916
Other income recognised in the current year	(904)	(1,080)
Change in estimates related to uncertain tax position[1]	(796)	-
Other changes in estimates	(181)	(366)
Additional research and development incentive	-	269
Closing balance	**1,858**	**3,739**

Presentation of balances

	2024 $000	2023 $000
Current	38,444	38,998
Non-current	7,683	15,947
Total deferred revenue	**46,127**	**54,945**

[1] Refer to discussion in Note 6 on change in estimate relating to an uncertain tax position.

13. Other liabilities

	2024 $000	2023 $000
Contingent consideration	-	6,188
Deferred consideration	1,475	-
Other payables	2,474	3,651
Other current liabilities	**3,949**	**9,839**
Deferred consideration	2,708	-
Other non-current liabilities	**2,708**	**-**

Other payables

Included in other payables is an amount of $2,174,000 in relation to reverse factoring arrangement that provides Nuix with predictable monthly payments for insurance premiums covering the period December 2023 until December 2024 (30 June 2023: $3,051,000).

The arrangement does not significantly extend the payment terms beyond normal terms agreed with other suppliers for insurance coverage that is received and used on a ratable basis.

Contingent consideration payable

The Group recognises liabilities measured at fair value in relation to contingent consideration arising out of acquisitions made by the Group. The contingent consideration is designated as a financial liability measured at fair value, and is deemed to be a Level 3 measurement of fair value. It has been discounted accordingly based on estimated time to complete a number of milestones. As part of the assessment at each reporting date, the Group considers a range of reasonably possible changes for key assumptions and has not identified any instances that could cause the fair value of contingent consideration to change significantly. Changes in the fair value of contingent consideration after acquisition date are recognised in profit and loss, unless the changes are measurement period adjustments.

A reconciliation of the movements in fair value measurements of contingent consideration is provided below.

Contingent consideration	2024 $000	2023 $000
Opening balance	6,188	13,856
Additions	3,974	-
Foreign exchange difference	30	165
Change in fair value estimate	(2,137)	(1,011)
Unwinding of interest	326	68
Transfers to deferred consideration as contingency has been resolved	(4,124)	-
Cash payments	(1,793)	(6,890)
Settled through the issuance of shares	(2,464)	-
Closing balance	**-**	**6,188**

The effect on profit and loss for the year is due to unwinding of interest on the contingent consideration, and change in fair value estimate due to reassessments of achievability of earnout milestones post-acquisition as indicated in the above reconciliation.

During FY24, in relation to the earnout payments in connection with the acquisition of Topos Labs by Nuix, an amount of USD $1,500,000 in cash was paid in April 2024, and a further USD $2,100,000 in Nuix Limited shares was issued in May 2024 to the sellers of Topos.

- Of the cash payment, USD $1,151,000 (AUD $1,793,000[1]) related to consideration for the business combination which had been included in contingent consideration payable, and USD $349,000 (AUD $543,000) related to consideration for post combination employee benefit arrangements.
- Of the share-based payment, USD $1,612,000 (AUD $2,464,000) related to consideration for the business combination which had been included in contingent consideration payable, and USD $488,000 (AUD $746,000) related to consideration for post combination employee benefit arrangements.

As discussed in Note 18, in 2H FY24 it was determined that the milestones to which the contingent consideration in the agreement to purchase Rampiva had been achieved, and accordingly as the liability is no longer contingent on future events occurring, the balance for the consideration has been transferred from contingent consideration to deferred consideration as of 30 June 2024.

Sensitivity

Generally, the fair value measurements of the milestones are sensitive to reasonably possible changes in unobservable inputs to their measurement, including the time frame over which milestones may (or may not) be achieved; the successfulness of integration of the acquired Intellectual Property with the Nuix platform; and the pace at which commercial activities proceed.

As there are no remaining milestones for the Topos acquisition, and the remaining milestones yet to be paid out for the Rampiva acquisition have been determined to have been met, there is no ongoing sensitivity to remeasurement of contingent consideration as of 30 June 2024.

Deferred consideration payable – liability-classified, equity-settled

Deferred consideration represents the amount payable on acquisition which is time-based, and not subject to ongoing performance conditions.

The deferred consideration is designated as a financial liability measured at fair value and deemed to be a Level 2 measurement of fair value. This measurement of fair value is determined with reference to the market-based discount rates for time value, for known amounts that will be settled at a future date. As part of the assessment at the reporting date, the Group has considered a range of reasonably possible changes for key assumptions and has not identified instances that could cause the fair value of deferred consideration to change significantly.

During the year ended 30 June 2024, certain milestones to which contingent consideration was recognised on acquisition date were confirmed as having been met. As such, to the extent that these liabilities remain on foot and are subject to settlement at a later date they are no longer contingent, and have been reclassified as deferred consideration payable.

The deferred consideration recognised as of 30 June 2024 relates to obligations to deliver to sellers of acquired businesses, a certain USD value of shares of Nuix Limited at specific times.

Deferred consideration – liability classified equity settled	2024 $000	2023 $000
Opening balance	-	-
Transfers from contingent consideration	4,123	-
Unwinding of interest	60	-
Closing balance – liability classified equity settled deferred consideration	**4,183**	-

[1] Referred to as "Payments of consideration for Topos Labs, LLC" in the cash flows from investing activities

14. Borrowing facility

Secured liabilities

During the year, Nuix Limited has entered into an agreement with The Hongkong and Shanghai Banking Corporation, Sydney Branch (HSBC), to provide a AUD $30,000,000 multicurrency revolving credit facility to the Company. HSBC has committed to provide the debt facilities under a new secured facility agreement ("Facility Agreement"), subject to the satisfaction of customary conditions precedent.

Overview of Facility Agreement Terms:

- Facility Amount: AUD $30,000,000 with an AUD $2,000,000 bank guarantee sub-limit.
- Maturity of three years.
- The new facility is to be utilised for general corporate purposes of the Company, other than costs associated with litigation, arbitration or administrative proceedings.
- The Facility Agreement includes customary representations and warranties, undertakings and events of default and review events for a financing of this nature.
- Amounts owing under the Facility Agreement are secured by the assets of the Company and its material subsidiaries.

The company has a CBA bank guarantee for the amount of $746,460 to support Nuix Limited's obligation for a property lease for its headquarters in Australia. This obligation is cash backed by the Group. Nuix Limited's obligations in respect to the bank guarantee are contingent only.

15. Issued capital

Movements in ordinary shares	2024 Shares	2023 Shares	2024 $000	2023 $000
Opening balance	317,499,158	317,314,794	370,696	370,696
Shares issued – acquisition of Rampiva	3,578,179	-	3,041	-
Shares issued – acquisition of Topos[1]	1,507,065	-	3,210	-
Shares issued – employee performance rights	944,384	184,364	-	-
Closing balance	**323,528,786**	**317,499,158**	**376,947**	**370,696**

Ordinary shares participate in dividends and the proceeds upon winding up of the Company, proportionately to the shareholding. At the shareholders' meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands. The issued shares do not have a par value.

Management controls the capital of the Group in order to maintain an appropriate debt to equity ratio, provide the shareholders with returns and ensure that the Group can fund its operations and continue as a going concern. The Group's debt and capital includes ordinary share capital and financial liabilities, supported by financial assets. There are no externally imposed capital requirements aside from debt covenants. Management effectively manages the Group's capital by assessing the Group's financial risks and adjusting its capital structure in response to changes in these risks and in the market. These responses include the management of debt levels, distributions to shareholders and share issues.

[1] On 11 April 2024 it was agreed with the sellers of Topos that 1,507,065 shares of Nuix Limited and a payment of US $1,500,000 would be made in settlement of the remaining earnout milestones. This agreement resulted in the derecognition of balances for contingent consideration and employee benefit obligations which had been recognised as of 31 December 2023.

16. Reserves

Foreign currency translation reserve

The foreign currency translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.

Share option reserve

The share option reserve is used to recognise the value of equity-settled share-based payments provided to employees, including key management personnel, as part of their remuneration.

Treasury share reserve

The reserve for the Company's treasury shares comprises the cost of the Company's shares acquired and transferred to settle share-based payment arrangement.

Movements in reserves	2024 $000	2023 $000
Share based payment reserve		
As at 1 July	(165,441)	(168,731)
Share-based payment arrangement	6,688	3,466
Settlement of share-based payment arrangements	-	(176)
As at 30 June	**(158,753)**	**(165,441)**
Foreign currency translation reserve		
As at 1 July	9,266	5,192
Foreign currency translation movement in period	(2,115)	4,074
As at 30 June	**7,151**	**9,266**
Treasury share reserve		
As at 1 July	-	-
Treasury shares acquired	-	176
Less: Shares transferred to settle share-based payments arrangement	-	(176)
As at 30 June	**-**	**-**
Total Reserves	**(151,602)**	**(156,175)**

17. Reconciliation of cash flows from operating activities

	2024 $000	2023 $000
Cash flows from operating activities		
Profit/(Loss) for the year (before income tax)	8,168	(5,274)
Non-cash charges recognised in profit and loss:		
Depreciation	3,681	4,305
Amortisation of intangible assets	46,430	36,386
Amortisation of capitalised borrowing costs	-	14
Bad debts expense	100	956
Share based payment expense	6,723	3,514
Net exchange rate differences	220	(34)
Fair value gain on contingent consideration	(2,137)	(1,011)
Changes in assets and liabilities:		
Decrease in trade and other receivables	(6,736)	(19,584)
Decrease in deferred tax asset	(7,153)	(156)
(Increase) / decrease in other current assets	(1,365)	713
Decrease in trade and other payables	(6,627)	(2,585)
(Decrease) / increase in deferred revenue	(8,818)	5,758
Increase in employee benefits provisions	6,509	4,458
Decrease in current tax liabilities	(2,223)	(316)
Increase in deferred tax liabilities	13,598	-
(Decrease) / increase in other liabilities	(103)	5,371
Increase in provision for make good	76	49
Net cash from operating activities	**50,343**	**32,564**

18. Acquisition of Rampiva

The Group acquired all of the shares of Rampiva Global, LLC and Rampiva Technology, Inc. (collectively Rampiva) on 1 July 2023 a workflow automation and job scheduling software provider. Rampiva is a long-term Nuix technology partner founded in 2016 to meet greater productivity demands for Nuix customers by automating their data processing tasks. Rampiva is used by customers where the cost, ease and administration of hyper-scale data processing is no longer sustainable manually.

In the period since acquisition to 30 June 2024, Rampiva recorded a profit of AUD $5,696,000, inclusive of expenses for amortisation of acquired intangibles and related deferred tax expense impacts of AUD $1,474,000, but excluding any specific allocation of sales and distribution costs of the existing Nuix business which facilitated the sales of Rampiva products. Included in this profit/loss since acquisition, are post-acquisition revenues of AUD $7,664,000.

The Group incurred acquisition-related costs of AUD $547,472 relating to external legal fees and legal due diligence costs. These costs have been included in 'general and administrative expenses'.

A. Consideration

The following table summarises the acquisition-date fair value of each major class of consideration transferred.

	Notes	$000
Cash		4,135
Shares		3,041
Contingent consideration	13	3,974
Total consideration		**11,150**

The initial cost of the acquisition includes US $2,000,000 in cash (subject to working capital adjustments on financial close), and US $2,000,000 in Nuix newly issued shares payable on financial close. As of the date of acquisition, up to a further US $3,000,000 in Nuix shares would be issued if Rampiva achieved specific ACV growth and cost management target milestones in the three years post-acquisition.

Contingent consideration that is part of the arrangement to acquire Rampiva, as its purpose is to verify or establish the fair value of the acquired business and its payment is not contingent on continued employment or service provision is measured at fair value as described in Note 13.

The acquisition date fair value of the then contingent consideration assessed to be part of the arrangement to acquire Rampiva, was determined to be AUD $3,974,000.

Post acquisition, in 2H FY24 it has been positively determined that the objective of these milestones have been met, and that US $3,000,000 in Nuix shares will be issued to the sellers of Rampiva, consistent with the provisions of the Equity Purchase Agreement. The agreement allows Nuix to make a determination in its sole discretion that the performance objectives of the earnout arrangements have been achieved, and to remove any uncertainty for the parties to the transaction, prior to the full three year term of the earnout arrangement being completed.

The settlement of this amount, notwithstanding this determination by Nuix, continues to be staged over a three-year period. The number of shares that will ultimately be issued in each of the next three years, is determined with reference to the volume weighted average price (VWAP) of Nuix Limited shares in the lead up to each of the three payment dates, where US $1,000,000 in Nuix Limited shares will be issued to the sellers of Rampiva.

The Group has reclassified this consideration as deferred consideration, rather than contingent consideration as of 30 June 2024, as the payment of the consideration is no longer contingent on a future event (refer Note 13).

B. Identifiable assets acquired and liabilities assumed

The following table summarises the recognised amounts of assets acquired and liabilities assumed at the date of acquisition.

	$000
Cash and cash equivalents	572
Trade receivables	885
Trade and other payables	(561)
Brand	112
Customer relationships	140
Intellectual property	8,368
Deferred tax liabilities	(2,261)
Total identifiable net assets acquired	**7,255**

Given the trade receivables at acquisition date were identified to be primarily with corporations with low credit risk and a short term to contractual receipt, the fair value of the receivables was measured at the gross contractual amounts receivable, and this represents management’s best estimate at acquisition date of the contractual cash flows that are expected to be collected.

C. Goodwill

Goodwill arising from the acquisition has been recognised as follows:

	Notes	$000
Fair value of consideration	A	11,150
Fair value of total identifiable net assets	B	7,255
Goodwill		**3,895**

The goodwill is primarily related to growth expectations, expected future profitability, the skills and technical talent of Rampiva's workforce, and expected synergies to be achieved from integrating the Rampiva software into the Group's existing products. As the customer base of Rampiva is substantially integrated with that of the Nuix, goodwill recognised on acquisition has been allocated in full to the Nuix platform CGU.

To the extent goodwill arises from the acquisition of Rampiva Global, LLC being $945,000 (USD $626,000 converted at acquisition date), it is considered to be deductible for tax purposes in the United States.

D. Measurement period adjustments

The details of the fair value on acquisition of identifiable assets acquired, liabilities assumed and goodwill determined as set out in this note are considered final, as the measurement period for acquisition accounting has closed. Accounting for the acquisition initially required assets acquired and liabilities assumed to be measured on a provisional basis, as the Group continued to obtain information relating to the determination of tax bases of acquired assets, and assumed liabilities.

During the measurement period extending to the 12 months post-acquisition, adjustments have been made to increase the provisional valuation of the intellectual property by $140,000, reduce the deferred tax liabilities recognised by $1,032,000, and decrease goodwill by $1,173,000 from amounts initially reported in 1H FY24.

19. Earnings per share

	2024 $000	2023 $000
Profit/(Loss) for the year	5,026	(5,589)
Weighted average number of ordinary shares (basic)	323,528,786	317,375,912
Basic earnings per share (in dollars)	**0.02**	**(0.02)**
Profit/(Loss) for the year	5,026	(5,589)
Weighted average number of ordinary shares (basic)	323,528,786	317,375,912
Shares issuable in relation to equity-based compensation schemes	19,254,613	9,595,860[1]
Effect of share options and performance rights	Dilutive	Antidilutive[2]
Diluted weighted average number of ordinary shares	333,124,646	326,971,772
Diluted earnings per share (in dollars)	**0.02**	**(0.02)**

[1] Comprises potential ordinary shares issuable in relation to performance rights. Options are only considered in the calculation of diluted earnings per share when the current share price exceeds the option exercise price (in the money options). With the exception of 2,623,841 options issued pre-IPO, the share options that remain on-foot and are fully vested have exercise prices higher than the current share price, and therefore do not give rise to potential ordinary shares that are used in the calculation of diluted earnings per share.

[2] In the year ended 30 June 2023, the conversion of the options and performance rights on issue would reduce the loss per share.

Potential ordinary shares are 'antidilutive' when their conversion to ordinary shares would decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share.

As a result, the effect of share options and performance rights on diluted earnings per share is considered to be 'antidilutive' in the year ended 30 June 2023.

20. Contingencies

On the basis that the Group has determined the below matters to be contingent liabilities, no liabilities have been recognised in the financial statements in relation to these matters.

ASIC proceedings

As advised to the market on 29 September 2022, ASIC commenced civil proceedings in the Federal Court against the Company (and its directors during the relevant period) alleging that from 18 January 2021 to 21 April 2021, aspects of the Company's market disclosures contravened provisions of the *Corporations Act 2001* and *ASIC Act 2001*. ASIC seeks declarations in respect of the alleged contraventions, pecuniary penalties against Nuix and pecuniary penalties and disqualification orders against the relevant directors.

Nuix has fully cooperated with ASIC during the course of its investigation into these matters. Nuix denies the allegations made by ASIC and filed its defence to the claim on 23 December 2022. The ASIC claim was heard in November and December 2023 and Nuix is awaiting judgment which is currently reserved in this matter.

Class Action

Nuix is the subject of a consolidated class action in the Supreme Court of Victoria which has been commenced on behalf of persons who acquired interests in Nuix shares in the period between 18 November 2020 and 29 June 2021. The proceeding also names Macquarie Capital and a former Macquarie Capital nominated director of Nuix as defendants in the proceedings.

In essence, the claim alleges that information disclosed in Nuix's Prospectus dated 18 November 2020 and certain market disclosures regarding its forecast FY21 revenue and performance in the period following the Company's IPO in December 2020 were misleading and contravened provisions of the *Corporations Act 2001* (Cth), the *ASIC Act* 2001 (Cth) and the Australian Consumer Law. The claim seeks damages on behalf of Group Members, but no amount of damages has yet been identified.

Nuix denies the allegations contained in the consolidated claim and filed its defence on 4 November 2022. The Second and Third Defendants (Macquarie Capital (Australia) Limited and Mr Daniel Phillips) have also filed defences denying the allegations contained in the consolidated claim. The matter has not yet been set down for a hearing.

Bank guarantee

The Company has obtained a bank guarantee in the amount of $746,460 (30 June 2023: $746,460) to secure certain obligations of the Company that arise under a commercial property lease. This obligation is cash backed by the Group.

21. Events after the reporting date

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial periods.

TAKE OWNERSHIP_ AND FOLLOW UP

RESILIENT_ WE LEARN FROM THE PAST AND ARE OPTIMISTIC ABOUT TOMORROW

UNAFRAID_ TO DO THE RIGHT THING, QUICKLY

TEAM NUIX_ FIRST AND FOREMOST

HERO OUR CUSTOMERS_ AND INNOVATE FOR THEM

Nuix (www.nuix.com, ASX:NXL) is a leading provider of investigative analytics and intelligence software, that empowers customers to be a force for good by finding truth in the digital world. We help customers collect, process and review massive amounts of structured and unstructured data, making it searchable and actionable at scale and speed with forensic accuracy.

APAC
Australia: +61 2 8320 9444

EMEA
UK: +44 203 934 1600

NORTH AMERICA
USA: +1 877 470 6849